Navigation Links
Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
Date:9/12/2007

information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

Other Information

In August, Ms. Karen Terrick joined Sunesis as a Director, Regulatory Affairs. In conjunction with her joining, the Compensation Committee of the company's Board of Directors approved an employment commencement grant to Ms. Terrick of a non-qualified stock option to purchase 25,000 shares of Sunesis common stock, effective August 31, 2007. This option award was granted without shareholder approval pursuant to Nasdaq Marketplace Rule 4350 (i)(1)(A)(iv) and with the following material terms: (a) an exercise price equal to the fair market value of the company's common stock on the grant date, (b) a term of ten years, and (c) a vesting schedule providing that the option is exercisable as to one-quarter of the total grant on the first anniversary of Ms. Terrick's hire, and one-forty-eighth of the total grant each month thereafter until the grant is fully vested.

Safe Harbor Statement

This press release contains forward-looking statements, including without limitation statements related to the safety, tolerability and potential efficacy of SNS-595 (alone and in combination with cytarabine) and SNS-314, planned clinical testing and development efforts and the anticipated clinical sites and timing of clinical trials. Words such as "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, Sunesis' drug discovery, development and clinical manufacturing activities could be halted or significantly delayed, Sunesis' clinical trials for SNS-59
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
4. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
5. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Calif. , Oct. 22, 2014 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery ... today announced that it has demonstrated human ... ongoing clinical study evaluating RG-101, a wholly-owned, ... treatment of hepatitis C virus infection ("HCV").  ...
(Date:10/20/2014)... MOUNTAIN VIEW, California , 20 de octubre ... un líder en el campo de la pulmonología ... en su Estudio RENEW, casi 3 meses antes ... prueba fundamental de exención de dispositivo de investigación ... y Medicamentos) para el sistema de espiral de ...
(Date:10/20/2014)... Oct. 20, 2014  ResMed (NYSE: ... ResMed Data Exchange program, a comprehensive suite of ... (HME) and other health care providers. ... to critical patient information. It integrates valuable sleep ... U-Sleep™ patient management platforms with customers, in-house or ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2
... this weeks issue of Science,researchers from the National ... in Sweden report an,important discovery about a critical ... plays in replicating DNA in higher organisms,such as ... places us one step closer to understanding the ...
... that HIV patients can live,longer lives, PASADENA, Calif., July ... combination with a second newer agent,has proven to be ... to be published in its July 7th,special HIV/AIDS issue. ... 18,nations and more than 30 centers in the United ...
Cached Medicine Technology:NIEHS Researchers Identify Enzyme Critical in DNA Replication 2NIEHS Researchers Identify Enzyme Critical in DNA Replication 3New Drugs in Multinational Study Show Promise in Fighting,Drug-Resistant HIV 2New Drugs in Multinational Study Show Promise in Fighting,Drug-Resistant HIV 3
(Date:10/22/2014)... -- The United States is now mandating that ... West Africa land at one of five airports ... virus. In a statement released Tuesday, Homeland ... of air passengers from Guinea, Liberia and Sierra ... airports -- New York City,s Kennedy International Airport, ...
(Date:10/22/2014)... The Louis W. Sullivan Institute ... distribute health information technology innovation to transform quality ... development of six key guiding principles of patient-centered ... These are an expansion of the Institute of ... is respectful of and responsive to individual patient ...
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment period starting ... Research (AIR) finds that three out of four Americans are ... percent say they are not likely or only somewhat likely ... , The AIR survey found wide gaps in Americans’ health ... how much they owe for a routine doctor’s visit. , ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most ... recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the ... the world. , “iPower is one of the most ... various kinds of useful products for new and old ... customer service and a number of features which will ...
(Date:10/22/2014)... Weight Your Body’s Way , In a world where a ... certainly can be difficult to choose the right weight loss ... doing it the healthy way? Set aside the fads and ... exercise regularly, and choose foods with the most nutritional benefits. ... to exercise more and eat less. Despite the number of ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2
... married life beat stress better than those live single, says ... buster//. ,Popular perception is that single people have a ... a loving relationship makes it easier to cope with the ... Daily Mail. ,Psychologist Dr Roxane Gervais monitored the ...
... ribosome is the protein-producing nanomachine in cells that keeps ... of Maryland researchers// has provided a clue that could ... HIV AIDS and SARS. ,In the March ... Maryland biology professor Jonathan Dinman and research assistant professor ...
... at Weill Cornell Medical College could prove a potent weapon ... called SS31, is able to cross the blood-brain barrier and ... damage. ,"In our experiments, we found that exposing ... a much smaller area of brain tissue being affected," says ...
... news for working couple in India. A study in the US ... more tended// to become disruptive in class. The effect persisted through ... of the child’s sex or family income, and regardless of the ... $200 million project financed by the National Institute of Child Health ...
... has approved four new drugs manufactured by the Macleods of ... of the four would be used against some strains of ... these four medicines will reinforce efforts to scale up access ... a statement. ,The medicines are the first TB ...
... that some foods and supplements do have an important role ... ‘big C’. At the 233rd national meeting of the American ... papers on this topic will be presented. ,Selected ... for preventing cancer of the esophagus, colon — Using animal ...
Cached Medicine News:Health News:New Ribosome Finding Could Lead to Antiviral Therapies 2Health News:Antioxidant Molecule Could Help Minimize Stroke-Linked Brain Damage 2Health News:Poor Behavior Is Linked to Time in Day Care 2Health News:Indian Pharma Authorized to Market New Anti-TB Drugs 2Health News:Emboldened Warriors-Cancer Fighting Foods 2Health News:Emboldened Warriors-Cancer Fighting Foods 3
Ideal for chest procedures....
Male Compression Vests...
Female Compression VEST w/sleeves...
Male Support Brief...
Medicine Products: